Voila! provides a streamlined workflow with an integrated statistical module, so researchers can obtain statistically meaningful results without the need for additional expertise and software.
La Jolla, CA (PRWEB) March 02, 2012
RNA sequencing is rapidly becoming a routine tool for many researchers. The data from RNA-Seq experiments is more expansive and detailed than from other technologies for transcriptome analysis, including microarrays. However, the optimal analysis of RNA-Seq datasets presents bioinformatics challenges for general users.
The Voila! cloud-based data analysis service offered by Prognosys Biosciences is optimized to accurately reduce large RNA-Seq data into output suitable for downstream statistical analysis. However, this downstream analysis requires additional statistical expertise and software. Voila! now overcomes this barrier with the inclusion of a user-friendly study-level analysis workflow. The new module guides users through study design, automatically selects appropriate statistical methods, performs differential expression and splicing analysis, and integrates significant associations with gene ontology terms. The results files are vastly reduced in size from the raw data and can be easily manipulated in spreadsheet format. Together with several graphical outputs, these results serve as an excellent starting point for the exploratory analysis of differential expression for user-defined variables of interest.
Bioinformatician Wayne Delport explains, “Researchers utilizing RNA-Seq require efficient data reduction and the application of rigorous statistical methods. Voila! provides a streamlined workflow with an integrated statistical module, so researchers can obtain statistically meaningful results without the need for additional expertise and software. Rather, researchers can focus on using these results to address biological questions more rapidly and effectively.”
Study design is often overlooked when planning RNA-Seq experiments, resulting in limited power for the detection of differential expression. In this regard, Prognosys’s Next-Gen Sequencing division, Sequensys, provides assistance with experimental design based on the goals of your study. “It may increase the cost to sequence additional biological replicates, but it is worthwhile if your sequencing project yields statistically significant results. Why would you perform an experiment that does not produce adequate power to answer your study questions?” adds Jill Dombrauckas, Marketing Director for Prognosys.
The Voila! RNA-Seq analysis pipeline was validated using both simulated and empirical data. These validation studies demonstrated better mapping quality of the Voila! analysis pipeline, when compared to current tools, resulting in improved detection of differential expression and splicing.
Prognosys will be exhibiting at the upcoming CHI X-Gen Congress in San Diego, CA March 6-8th. If attending, please visit booth 22 for more information.
For more information about Voila!™ cloud-based data analysis services, please visit voila.prognosysbio.com or contact info(at)prognosysbio(dot)com. Next generation sequencing services are also available through Sequensys®, a division of Prognosys Biosciences (http://www.prognosysbio.com/sequensys).
About the Company:
Prognosys Biosciences® is focused on the promising and rapidly developing field of personalized medicine. We develop novel genomic and proteomic technologies to enable research discoveries and clinical applications. Prognosys has extensive expertise in the areas of assay development and biomarker discovery, as well as implementation of next-generation sequencing technologies for the analysis of complex biological systems.